- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00596388
Usage of the Home Macular Perimeter (HMP) (HMP)
May 14, 2013 updated by: Notal Vision Ltd.
Usage of the Home Macular Perimeter (HMP) in Intermediate Age Related Macular Degeneration Patients Pilot Study
Demonstrate the ability of the current interactive tutorial and 1-800 support to teach an AMD patient to use the HMP device.
Study Overview
Status
Completed
Conditions
Detailed Description
The pilot study purpose is to demonstrate that the tutorial which is part of the device software, is giving sufficient training for the intended users.
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Afula, Israel
- Haemek Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
• Subjects diagnosed as intermediate AMD
Description
Inclusion Criteria:
- Capable and willing to sign a consent form and participate in the study
- Subjects diagnosed as intermediate AMD in at least one eye
- Age >50 years
- VA with habitual correction >20/60 in the study eye
- Ability to speak, read and understand instructions in Hebrew
- Familiar with computer usage
Exclusion Criteria:
- Evidence of macular disease other than AMD or glaucoma in the study eye
- Presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy, CFP.
- Any non-macular related ocular surgery performed within 3 months prior to study entry in the target eye
- Participation in another study with the exclusion of AREDS study
- Patients diagnosed with geographic atrophy (GA)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
1
Subjects diagnosed as intermediate AMD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of subjects who manage to use the device as in a daily testing
Time Frame: 6 month
|
6 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yaron Mr Lang, MD, HaEmek Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (Actual)
January 1, 2013
Study Completion (Actual)
March 1, 2013
Study Registration Dates
First Submitted
January 7, 2008
First Submitted That Met QC Criteria
January 7, 2008
First Posted (Estimate)
January 17, 2008
Study Record Updates
Last Update Posted (Estimate)
May 15, 2013
Last Update Submitted That Met QC Criteria
May 14, 2013
Last Verified
May 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HMP-PU1
- 0197-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age Related Macular Degeneration
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular DegenerationRussian Federation
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hui PengNot yet recruitingNeovascular Age-related Macular Degeneration(nAMD)
-
Rophibio, Inc.Not yet recruitingNeovascular Age-related Macular Degeneration (nAMD)United States
-
Notal Vision Inc.CompletedNeovascular Age-related Macular Degeneration | Intermediate Age Related Macular Degeneration (Disorder)United States
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationAustria, Germany, Spain, Israel, France, Taiwan, Belgium, United States, United Kingdom, Argentina, Italy, Australia, Switzerland, Brazil, Turkey (Türkiye)
-
Innostellar Biotherapeutics Co.,LtdActive, not recruitingNeovascular Age-Related Macular DegenerationChina
-
Ophthotech CorporationCompletedNeovascular Age-Related Macular DegenerationUnited States